Skip to content
DataLookout
Menu

PRO-HEBNCT05424016

Propranolol and Von Hippel-Lindau Disease

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2022 to Jan 16, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

total and individual hemangioblastomas' volume measured by MRI
Timeframe: 24 months

Secondary (7)

To compare the safety (tolerance) between the two treatment arms at 24 months post-randomization
To Compare the growth rate of HB between the two treatment arms at 24 months post-randomization
Compare the extent of peritumoral edema between the two treatment arms
Compare the development of de novo lesions between the two treatment arms every 6 months
Compare the angiogenic profile of BHs between the two groups every 6 months
Show 2 moreShow less
Study the evolution of serum VEGF level under treatment at 12 and 24 months
Compare the number of patients requiring surgery between the two treatment arms

Arms and interventions

Experimental armExperimental

Patients with no contraindications will be included and randomized to receive propranolol orally for 24 months

control armOther

Patient included with a routine follow-up

Drugs: Propranolol

Other: follow-up

Sites

1 site in 1 country

  • AP-HP, Bicêtre HospitalLe Kremlin-Bicêtre, France